Evidence map›Paper›PMID 36798298›Full record

ArticlebioRxiv : the preprint server for biology2023

Transmissibility of clinically relevant atovaquone-resistant

Victoria A Balta, Deborah Stiffler, Abeer Sayeed, Abhai K Tripathi, Rubayet Elahi, Godfree Mlambo, Rahul P Bakshi, Amanda G Dziedzic, Anne E Jedlicka, Elizabeth Nenortas and 8 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 2 institutions in 2 countries.

Victoria A BaltaW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Deborah StifflerW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Abeer SayeedW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Abhai K TripathiW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Rubayet ElahiW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Godfree MlamboW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Rahul P BakshiThe Johns Hopkins Malaria Research Institute, Baltimore, MD, 21205.
Amanda G DziedzicW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Anne E JedlickaW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Elizabeth NenortasDivision of Clinical Pharmacology, Departments of Medicine and of Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore, MD, 21205-2186.
Keyla Romero-RodriguezDivision of Clinical Pharmacology, Departments of Medicine and of Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore, MD, 21205-2186.
Matthew A CanonizadoDivision of Clinical Pharmacology, Departments of Medicine and of Pharmacology and Molecular Sciences, The Johns Hopkins University, Baltimore, MD, 21205-2186.
Alexis MannW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Andrew OwenCentre of Excellence in Long-acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool L69 3BX, UK.
David J SullivanW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Sean T PriggeW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Photini SinnisW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Theresa A ShapiroW. Harry Feinstone Department of Molecular Microbiology and Immunology, The Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205.
Johns Hopkins University · USUniversity of Liverpool · GB

Funding

Essential PK/PD relationships of antimalarial drugsR01AI095453 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SHAPIRO, THERESA A · 2012 to 2024
$4.8M
The Skin Phase of Malaria Infection (Sharon Patray Diversity Supplement)R01AI132359 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SINNIS, PHOTINI · 2017 to 2021
$2.7M
Malaria and Mosquito/Tick-borne DiseasesT32AI138953 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DAVID Joseph SULLIVAN · 2019 to 2026
$2.0M
NIAID NIH HHS R01 AI095453NIAID NIH HHS R01 AI132359NIAID NIH HHS T32 AI138953
6 · The paper itself

Abstract

Rising numbers of malaria cases and deaths underscore the need for new interventions. Long-acting injectable medications, such as those now in use for HIV prophylaxis, offer the prospect of a malaria "chemical vaccine", combining the efficacy of a drug (like atovaquone) with the durability of a biological vaccine. Of concern, however, is the possible selection and transmission of drug-resistant parasites. We addressed this question by generating clinically relevant, highly atovaquone-resistant,

Indexed as

AnophelesatovaquoneBiological Sciencescytochrome bmalariaMicrobiologyPlasmodiumresistance

Identifiers

PMID36798298
PMCPMC9934642
OpenAlexW4319602882

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.